DALCORPHARMA.COM: Keyword Density Checker

Total words: 1436 | 2-word phrases: 366 | 3-word phrases: 411 | 4-word phrases: 424

PAGE INFO

Title	Try to keep the title under 60 characters (22 characters) DalCor Pharmaceuticals
Description	Try to keep the meta description between 50 - 160 characters (158 characters) DalCor is developing dalcetrapib, a precision pharmacogenetic medicine for patients with a heart attack to reduce the risk of recurrent myocardial infarction.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	No H1 tag on the page (0 characters)

#	Keyword	Frequency	Density
1	in the adcy9	3	0.73%
2	the aa genotype	3	0.73%
3	aa genotype at	3	0.73%
4	precision medicine for	3	0.73%
5	contact us fr	2	0.49%
6	dal302 study information	2	0.49%
7	study information for	2	0.49%
8	clinical trial sites	2	0.49%
9	email email protected united	2	0.49%
10	adcy9 aa genotype	2	0.49%
11	news press releases	2	0.49%
12	press releases contact	2	0.49%
13	releases contact us	2	0.49%
14	fatal and nonfatal	2	0.49%
15	the adcy9 gene	2	0.49%
16	dalgene2 trial dal302	2	0.49%
17	location in the	2	0.49%
18	rs1967309 location in	2	0.49%
19	of dalcetrapib to	2	0.49%
20	dalcetrapib to reduce	2	0.49%
21	at rs1967309 location	2	0.49%
22	genotype at rs1967309	2	0.49%
23	acute coronary syndrome	2	0.49%
24	nonfatal mi in	2	0.49%
25	genotype at variant	2	0.49%
26	trial dal302 study	2	0.49%
27	at variant rs1967309	2	0.49%
28	board of directors	2	0.49%
29	2000 patients with	2	0.49%
30	in 2000 patients	2	0.49%

#	Keyword	Frequency	Density
1	the aa genotype at	3	0.71%
2	location in the adcy9	2	0.47%
3	aa genotype at variant	2	0.47%
4	trial dal302 study information	2	0.47%
5	dal302 study information for	2	0.47%
6	news press releases contact	2	0.47%
7	press releases contact us	2	0.47%
8	releases contact us fr	2	0.47%
9	acute coronary syndrome acs	2	0.47%
10	genotype at variant rs1967309	2	0.47%
11	cardiovascular diseases publications clinical	2	0.47%
12	in 2000 patients with	2	0.47%
13	mi in 2000 patients	2	0.47%
14	genotype at rs1967309 location	2	0.47%
15	at rs1967309 location in	2	0.47%
16	rs1967309 location in the	2	0.47%
17	in the adcy9 gene	2	0.47%
18	dalgene2 trial dal302 study	2	0.47%
19	of dalcetrapib to reduce	2	0.47%
20	about dalcor management board	2	0.47%
21	cardiovascular diseases dalcetrapib history	2	0.47%
22	management board of directors	2	0.47%
23	dalcor management board of	2	0.47%
24	our science approximately 20	1	0.24%
25	adenylate cyclase type 9	1	0.24%
26	the adenylate cyclase type	1	0.24%
27	in the adenylate cyclase	1	0.24%
28	variant rs1967309 in the	1	0.24%
29	over 15000 patients with	1	0.24%
30	at variant rs1967309 in	1	0.24%
31	type 9 adcy9 gene	1	0.24%
32	cardiovascular diseases and risk	1	0.24%
33	diseases and risk factors	1	0.24%
34	carrying the aa genotype	1	0.24%
35	as carrying the aa	1	0.24%
36	identified as carrying the	1	0.24%
37	and identified as carrying	1	0.24%
38	n6147 and identified as	1	0.24%
39	13 months before randomization	1	0.24%
40	cyclase type 9 adcy9	1	0.24%

#	URL	Whois	Check
1	https://2point0media.com/	Whois	2point0media.com